Definium Therapeutics, Inc. 4

Chief Medical Officer Dan Karlin received an award of 100,000 common shares of Definium Therapeutics, Inc. as a performance-based equity grant.

On August 12, 2026, Definium Therapeutics, Inc. Chief Medical Officer Dan Karlin received 100,000 common shares as the second tranche of performance share units originally granted on March 12, 2025, at a stated price of $0.00 per share. These shares are part of an equity incentive arrangement and remain subject to vesting conditions tied to Dr. Karlin’s continued employment through March 12, 2028 and the achievement of specified clinical and regulatory milestones, increasing his directly held common share position to 603,282 shares. With no trading price disclosed in the filing or snapshot, the dollar value of both the grant and his post-transaction holdings cannot be precisely determined but should be viewed as routine equity compensation rather than an open‑market purchase or sale.

Filing Facts

CIK

1813814

Ticker

DFTX

Form

4

Source Type

fda

Accession

0001193125-26-345838

Alert Tier

5